The expression of miRNA‐146a‐5p and its mechanism of treating dry eye syndrome

Yin, Liang; Zhang, Mingxue; He, Tao; Chen, Song

doi:10.1002/jcla.23571

Cited by 10 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-146a plays a key role in the regulation of innate immunity and inflammation 11 – 14 . There was no significant difference in the expression of miR-146a in the blood of patients with dry eye disease and healthy people 36 , but the expression of miR-146a in the corneas of patients with dry eye disease and healthy people is not clear. In the present study, we explored the role of miR-146a in corneal inflammation using a dry eye mouse model and HCEC inflammation model.…”

Section: Discussionmentioning

confidence: 78%

MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye

Han

Gao

Wang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Inflammation is a key factor in the pathogenesis of dry eye disease (DED). We aimed to investigate the role of microRNA-146a (miR-146a) in regulating corneal inflammation in a mouse model of benzalkonium chloride (BAC)-induced dry eye and the TNF-α-induced NF-κB signaling pathway in human corneal epithelial cells (HCECs). A mouse model of dry eye was established by administering with BAC to BALB/c mice, and the expression of TNF-α, IL-1β, IL-6, IL-8, cyclooxygenase 2 (COX2), interleukin-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) in the corneas of dry eye model mice was significantly increased; this was accompanied by the upregulation of miR-146a and activation of the NF-κB pathway. In vitro, TNF-α induced miR-146a expression in HCECs, while the NF-κB inhibitor SC-514 reduced the expression of miR-146a. Overexpression of miR-146a decreased the expression of IRAK1 and TRAF6, which have been identified as targets of miR-146a. Furthermore, overexpression of miR-146a suppressed NF-κB p65 translocation from the cytoplasm to the nucleus. Moreover, overexpression of miR-146a attenuated the TNF-α-induced expression of IL-6, IL-8, COX2 and intercellular adhesion molecule 1 (ICAM1), while inhibition of miR-146a exerted the opposite effect. Our results suggest that miR-146a mediates the inflammatory response in DED. MiR-146a negatively regulates inflammation in HCECs through the IRAK1/TRAF6/NF-κB pathway, and this may serve as a potential therapeutic approach for the treatment of DED.

show abstract

Section: Discussionmentioning

confidence: 78%

MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye

Han

Gao

Wang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Moreover, miR-146a mitigates TNF-α-induced expression of IL-6, IL-8, COX2, and intercellular adhesion molecule 1 (ICAM1), suggesting that miR-146a-mediated inhibition of IRAK1 could potentially mediate the inflammatory response in DED [36]. Additionally, Yin et al [37] have shown that miRNA-146a-5p suppresses IRAK1, IL-6, TNF-α, and CBP expression, which reduces the inflammatory response in DED.…”

Section: Dry Eyementioning

confidence: 99%

Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects

Kim,

Hwang,

Hyun

et al. 2024

Molecules

View full text Add to dashboard Cite

Interleukin receptor-associated kinase (IRAK) proteins are pivotal in interleukin-1 and Toll-like receptor-mediated signaling pathways. They play essential roles in innate immunity and inflammation. This review analyzes and discusses the physiological functions of IRAK1 and its associated diseases. IRAK1 is involved in a wide range of diseases such as dry eye, which highlights its potential as a therapeutic target under various conditions. Various IRAK1 inhibitors, including Pacritinib and Rosoxacin, show therapeutic potential against malignancies and inflammatory diseases. The covalent IRAK1 inhibitor JH-X-119-01 shows promise in B-cell lymphomas, emphasizing the significance of covalent bonds in its activity. Additionally, the emergence of selective IRAK1 degraders, such as JNJ-101, provides a novel strategy by targeting the scaffolding function of IRAK1. Thus, the evolving landscape of IRAK1-targeted approaches provides promising avenues for increasingly safe and effective therapeutic interventions for various diseases.

show abstract

Non-invasive miRNAs for early detection and diagnosis of lacrimal adenoid cystic carcinoma

Ding,

Chen,

Liu

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Lacrimal adenoid cystic carcinoma (LACC) is one of the most common malignant epithelial tumors of the lacrimal gland, characterized by high rates of local recurrence, distant metastases, and tumor-related mortality. This malignancy impairs the lacrimal gland's ability to secret tears, thereby disrupting the normal function of the ocular surface. Due to ineffective diagnostic approaches and the complex anatomical location of the lacrimal gland within the orbit, many LACC patients are often diagnosed at the later stages. Therefore, it is urgent to develop a simple and convenient method for early detection of LACC through biomarker analysis by liquid biopsies, such as blood or tears. Various microRNAs (miRNAs) derived from liquid biopsies have been shown to serve as biomarkers for early diagnosis of tumors. In the present study, we screened LACC-specific miRNAs using miRNA microarray analysis in both primary and recurrent patient groups. We then validate their expression by qPCR experiments conducted in tissues, cell lines, tear fluid and serum to explore the association between these miRNAs and LACC development and prognosis. Our findings reveal that hsa-miR-200b-3p, hsa-miR-200c-3p and hsa-miR-141-3p are significantly upregulated in LACC, and the microarray data showed that these three miRNAs were significantly elevated in the recurrence group compared to the primary group. In conclusion, detecting miRNA expression in tear fluid and serum provides non-invasive biomarkers for the early diagnosis of LACC and may facilitate monitoring outcomes related to lacrimal gland diseases. Supplementary Information The online version contains supplementary material available at 10.1007/s12672-024-01436-9.

show abstract

The expression of miRNA‐146a‐5p and its mechanism of treating dry eye syndrome

Cited by 10 publications

References 26 publications

MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye

MicroRNA-146a negatively regulates inflammation via the IRAK1/TRAF6/NF-κB signaling pathway in dry eye

Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects

Non-invasive miRNAs for early detection and diagnosis of lacrimal adenoid cystic carcinoma

Contact Info

Product

Resources

About